Cost utility analysis of vinorelbine versus gemcitabine combined with cisplatin of advanced non-small cell lung cancer
-
摘要: 目的 评价长春瑞滨(NP)或吉西他滨GP)联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效和成本效用。 方法 60例晚期NSCLC患者,每组30例,化疗4周期后,评价疗效和成本效用。 结果 NP组和GP组治疗的有效率分别为36.6%和40.0%,中位生存期分别为8.52和8.37月,统计学检验发现两者之间的差异无统计学意义,P>0.05。NP组和GP组治疗的一年生存率分别为36.6%和33.3%;2年生存率分别为16.6%和13.3%,成本效用比分别为1 123.41和1 556.61。 结论 NP和GP方案治疗NSCLC疗效基本相似,但NP方案治疗的成本效用相对较好。Abstract: Objective To compare and evaluate the effectiveness and cost utility of vinorelbine versus gemcitabine combined with cisplatin of advanced non-small cell lung cancer. Methods 60 advanced patients wit NSCLC were enrolled into two groups, the effectiveness and cost utility were evaluated after 2 cycles. Results The efficacy rate wit NP and GP were 36.6%and 40.0% respectively, An existence period wit NP and GP were 8.52 and 8.37 respectively, showing no significant difference (P>0.05) between the two groups. One year survival rate with NP and GP were 36.6%and 40.0% respectively; two year survival rate with NP and GP were 16.6%and 13.3% respectively. The ratio of cost utility with NP and GP were 1123.41and 1556.61 respectively. Conclusion The effectiveness of NP versus GP of advanced non-small cell lung cancer was similar, the cost utility of NP was more than GP.
-
Key words:
- vinorelbine /
- gemcitabine /
- cisplatin /
- advanced non-small cell lung cancer /
- chemotherapy /
- cost utility analysis
-
[1] 陆舜. 肺癌患者的生存质量评价表[J].现代康复,2001,5(6):20. [2] 李灿,辛玲.调查问卷的信度与效度的评价方法研究[J].中国卫生统计,2008,25(5):541. [3] 李兆元,黄秋华,徐海声,等. 国产吉西他滨或长春瑞滨联合顺铂治疗进展期非小细胞肺癌的临床观察[J].现代肿瘤医学,2007,15(9):1255. [4] 谢强,陈群,李育宏,等. 吉西他滨和长春瑞滨对比治疗老年晚期非小细胞肺癌临床研究[J].临床肺科杂志,2009,14(1):50. -
![WeChat](/fileYXSJZZ/journal/article/yxsjzz/2012/6/PIC/wechat_cn_20120620.jpg)
计量
- 文章访问数: 4345
- HTML全文浏览量: 270
- PDF下载量: 1000
- 被引次数: 0